Frontiers in Immunology · 2013 · 48 citations · 21 references
MedicineOncologyPharmacologyInnate ImmunityMetastasisMolecular OncologyCancer ImmunotherapyInnate Immune ModulationInnate Immune Signaling PathwaysMelanoma ImmunotherapyMelanoma ProgressionMetastatic Melanoma TreatmentMevalonate PathwayMhc Class I MoleculesPeroxisome Proliferator-activated Receptor Gamma AgonismPeroxisome Proliferator-activated Receptor Gamma RegulationPeroxisome Proliferator-activated Receptor Signaling
Survival of melanoma patients after metastases detection remains short. Several clinical trials have shown moderate efficiency in improving patient survival, and the search for pharmacological agents to enhance the immune response and reduce melanoma metastases is still necessary. Statins block the mevalonate pathway, which leads to decreases in GTPase isoprenylation and activity, particularly those of the Ras superfamily. They are widely used as hypocholesterolemic agents in cardiovascular diseases and several studies have shown that they also have protective effects against cancers. Furthermore, we have previously demonstrated that treatment of melanoma cells with inhibitors of the mevalonate pathway, such as statins, favor the development of specific adaptive immune responses against these tumors. In the present study, we tested statin impact on the innate immune response against human metastatic melanoma cells. Our data shows that treatment of two human melanoma cell lines with statins induced a weak but significant increase of MHC class I Chain-related protein A (MICA) membrane expression. Peroxisome Proliferator-Activated Receptor gamma is involved in this statin-induced MICA overexpression, which is independent of Ras and Rho GTPase signaling pathways. Interestingly, this MICA overexpression makes melanoma cells more sensitive to in vitro lysis by NK cells. The impact of statin treatment on in vivo development of melanoma tumors and metastases was investigated in nude mice, because murine NK cells, which express NKG2D receptors, are able to recognize and kill human tumor cells expressing MICA. The results demonstrated that both local tumor growth and pulmonary metastases were strongly inhibited in nude mice injected with statin-treated melanoma cells. These results suggest that statins could be effective in melanoma immunotherapy treatments.
21
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
F. Stephen Hodi, Steven O’Day, David F. McDermott et al. · New England Journal of Medicine · 2010 · 15.2K citations · Full text
Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma
Caroline Robert, L. Thomas, Igor Bondarenko et al. · New England Journal of Medicine · 2011 · 4.5K citations · Full text
Medicine, Oncology, Pharmacotherapy +12
Inhibition of Mutated, Activated BRAF in Metastatic Melanoma
Keith T. Flaherty, Igor Puzanov, Kevin B. Kim et al. · New England Journal of Medicine · 2010 · 3.5K citations
Medicine, Oncology, Pharmacology +17
NKG2D-Deficient Mice Are Defective in Tumor Surveillance in Models of Spontaneous Malignancy
Nadia Guerra, Ying Xim Tan, Nathalie T. Joncker et al. · Immunity · 2008 · 813 citations · Full text